Effect of rebamipide ophthalmic suspension on the success of lacrimal stent intubation.
OBJECTIVE
To evaluate the effect of the postoperative administration of rebamipide ophthalmic suspension on the success rate of lacrimal stent intubation (LSI) for the treatment of primary acquired nasolacrimal duct obstruction (PANDO).


METHODS
This comparative interventional cohort study investigated 110 consecutive patients with PANDO who were treated with LSI and followed up for 12 months postoperatively at one institution. LSI was performed by one surgeon, and all patients received identical postoperative care. Among the total 110 patients, 71 underwent LSI with postoperative administration of rebamipide ophthalmic suspension, and 39 underwent LSI without administration of the suspension. Data related to patient age, gender, laterality, and postoperative administration of rebamipide ophthalmic suspension were collected and used as independent variables, and logistic regression analyses were performed to compare the anatomical success rate at 12 months postoperatively between patients with and without postoperative administration of the suspension.


RESULTS
The anatomical success rate of LSI in patients with and without postoperative administration of rebamipide ophthalmic suspension was 90.1 and 69.2 %, respectively. A comparison of these success rates showed statistical significance, in that the rate of treatment success was higher in PANDO patients who underwent LSI with postoperative administration of the suspension [odds ratio (OR), 3.37; P < 0.05].


CONCLUSIONS
The findings of this study show that postoperative administration of rebamipide ophthalmic suspension increases the rate of anatomical success in patients who undergo LSI for the treatment of PANDO.
Department of Ophthalmology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan. opt119@poh.osaka-med.ac.jp.|Department of Ophthalmology, Osaka Kaisei Hospital, Osaka, Japan. opt119@poh.osaka-med.ac.jp.
Masashi
M
Mimura
Department of Ophthalmology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan.
Mari
M
Ueki
Department of Ophthalmology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan.
Hidehiro
H
Oku
Department of Ophthalmology, Osaka Kaisei Hospital, Osaka, Japan.
Bunpei
B
Sato
Department of Ophthalmology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan.
Tsunehiko
T
Ikeda
D000368:Aged; D000369:Aged, 80 and over; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007440:Intubation; D007767:Lacrimal Duct Obstruction / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009301:Nasolacrimal Duct; D009883:Ophthalmic Solutions; D011182:Postoperative Care; D011379:Prognosis; D015363:Quinolones / Q000008:administration & dosage*; D015607:Stents; D013535:Suspensions
D000897:Anti-Ulcer Agents; D009883:Ophthalmic Solutions; D015363:Quinolones; D013535:Suspensions; C052785:rebamipide; D000409:Alanine
Intubation; Lacrimal stent; Nasolacrimal duct obstruction; Rebamipide